Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

274
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
274
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

245
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
245
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

538
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
538
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

424
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
424
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

690
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
690
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

34
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Community-based tuberculosis screening with computer-aided detection technology alone and in combination with point-of-care C-reactive protein testing: a paired screen-positive trial.

The Lancet. Infectious diseases·2026
Same author

Analytical performance of the VITAâ„¢ point-of-care CD4 enumeration assay.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

A novel model of care; Telemedicine and peer support for HCV care among HIV-infected people who inject drugs in remote Myanmar: a retrospective study.

Harm reduction journal·2026
Same author

Feasibility and outcomes of diabetes mellitus screening in people with tuberculosis in Burundi.

International health·2026
Same author

Prevalence of nontuberculous mycobacteria isolates and pulmonary disease from respiratory tract samples in persons investigated for presumed tuberculosis from three West African countries, an analysis of three prospective cohort studies.

BMC infectious diseases·2026
Same author

Genome-wide analyses of Mycobacterium tuberculosis complex isolates reveal insights into circulating lineages and drug resistance mutations in The Gambia.

Scientific reports·2026

Related Experiment Video

Updated: Oct 23, 2025

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.3K

Pretomanid for tuberculosis: a systematic review.

Tinne Gils1, Lutgarde Lynen1, Bouke C de Jong2

  • 1Unit of HIV and Coinfections, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|August 17, 2021
PubMed
Summary
This summary is machine-generated.

Pretomanid shows promise in treating drug-resistant tuberculosis, demonstrating efficacy in reducing bacterial load and achieving favorable outcomes. Further trials are needed to compare pretomanid with existing drugs and define its role.

Keywords:
EfficacyNew drugsSafetySystematic reviewTuberculosis

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K

Related Experiment Videos

Last Updated: Oct 23, 2025

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.3K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K

Area of Science:

  • Pharmacology and Infectious Diseases
  • Clinical Trial Analysis
  • Drug Efficacy and Safety

Background:

  • Systematic review of pretomanid-containing regimens for tuberculosis treatment is lacking.
  • Pretomanid is a novel drug investigated for its efficacy against Mycobacterium tuberculosis.

Purpose of the Study:

  • To systematically review and appraise the existing evidence on the clinical efficacy and safety of pretomanid in tuberculosis treatment.
  • To evaluate the role of pretomanid in various forms of tuberculosis, including drug-susceptible, drug-resistant, and highly resistant strains.

Main Methods:

  • Searched major databases (PubMed, ClinicalTrials.gov, Cochrane Library) for quantitative studies on pretomanid.
  • Included studies involving patients with tuberculosis treated with pretomanid-containing regimens.
  • Extracted data on efficacy (bactericidal activity, treatment outcomes, resistance) and safety, assessing risk of bias.

Main Results:

  • Pretomanid-moxifloxacin-pyrazinamide showed superior early bactericidal activity and faster culture conversion in rifampicin-susceptible tuberculosis but was associated with hepatotoxicity.
  • In uncomplicated rifampicin-resistant tuberculosis, pretomanid-moxifloxacin-pyrazinamide achieved 91% favorable end-of-treatment outcomes.
  • In highly resistant tuberculosis, pretomanid-bedaquiline-linezolid resulted in 90% favorable outcomes, though linezolid toxicity was noted. No acquired resistance to pretomanid was observed.

Conclusions:

  • Pretomanid demonstrates significant potential in treating rifampicin-resistant and highly resistant tuberculosis.
  • Further comparative trials are essential to establish pretomanid's optimal role alongside existing tuberculosis drugs.